EN DE

TATA Health International Holdings (1255) Fair Value & Analysis

Consumer Cyclical · HK · Market cap HK$874M

TH TATA Health International Holdings 1255 · HK
PriceHK$2.20
Fair ValueHK$1.21
Upside-45.0%
Quality59/100
Watch TATA Health International Holdings for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Solidly profitable · 13.4% net margin
Negative equity (buybacks among others) · negative free cash flow
Mixed vs. peers (4/10)
Narrow moat 20/100
Evidence: Low Range HK$0.9100 – HK$1.51 Share as image

Fair value as of: Aug 13, 2026

From 7 valuation models · updated 2 days ago

Share price −17.0% over the past month.

A solid business, but screening 45% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (HK$1.51). The favourable scenario is already priced in.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
  • Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$8.20 HK$0.2800 Fair Value HK$1.21 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$0.2800 – HK$8.20 · fair‑value band HK$0.9100 – HK$1.51 · the HK$2.20 price screens above the HK$1.21 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

TATA Health International Holdings (1255) currently trades at HK$2.20, while our model-based Fair Value estimate is HK$1.21, implying the stock looks roughly 45.0% overvalued today. The Quality Score stands at 59/100 (solid quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, TATA Health International Holdings generated revenue of HK$99.8M at a net margin of 13.4%. Revenue grew 0.5% year over year. Net debt stands at HK$7.9M. The stock trades on a trailing P/E of 72.0 (as of Jul 2, 2026). Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$0.9100 (bear case) to HK$1.51 (bull case); at HK$2.20, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 42% below its 52-week high, currently above its 200-day average. For context, the median of 10 Consumer Cyclical peers we cover trades at 10% fair-value upside, at -45%, 1255 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Gordon GGM HK$0.1500 HK$0.1600 HK$0.1800 70
Growth-Adj P/E HK$0.6400 HK$0.9100 HK$1.19 68
P/E Multiple HK$0.9100 HK$1.21 HK$1.51 63
All 7 models by family
DCF Models
Owner Earnings HK$0.7800 HK$0.9900 HK$1.35 31
Earnings-Based
Graham-Dodd HK$0.3700 HK$0.4600 HK$0.5100 54
Dividend Discount
Gordon GGM HK$0.1500 HK$0.1600 HK$0.1800 70
DDM Multi-Stage HK$0.1500 HK$0.1800 HK$0.2100 61
Multiples
P/E Multiple HK$0.9100 HK$1.21 HK$1.51 63
P/S Multiple HK$0.3700 HK$0.4900 HK$0.6200 58
Growth Earnings
Growth-Adj P/E HK$0.6400 HK$0.9100 HK$1.19 68

Widest divergence: DCF Models (HK$0.9900) versus Dividend Discount (HK$0.1600). Highest evidence: Gordon GGM (70).

Notify me when 1255 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$99.8M
Revenue growth (YoY) +0.5%
Net margin 13.4%
Return on equity -6,765%
Free cash flow −HK$22.4M FY2025
P/E ratio 72.0 as of Jul 2, 2026
More key figures
Operating margin -3.5%
EPS (TTM) HK$-0.0200
Net debt HK$7.9M FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 59/100

Of which business quality 56 · Market factors (momentum, volatility) 58

Profitability 82
Margins and returns on capital today
Quality Growth 80
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 33
Balance sheet, leverage, solvency risk
Investment 97
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 85
Price trend over the last 3–12 months (market factor)
52W Momentum 77
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

TATA Health International Holdings Limited, an investment holding company, engages in the wholesale and retail of footwear products in Hong Kong, and Macau. The company operates through Trading of Footwear Products, Trading of Healthcare Products, Financial Services, and Online Medical Services segments. The company was formerly known as S.

Full company description

TATA Health International Holdings Limited, an investment holding company, engages in the wholesale and retail of footwear products in Hong Kong, and Macau. The company operates through Trading of Footwear Products, Trading of Healthcare Products, Financial Services, and Online Medical Services segments. The company was formerly known as S. Culture International Holdings Limited and changed its name to TATA Health International Holdings Limited in November 2020. TATA Health International Holdings Limited was incorporated in 2013 and is headquartered in Kwai Chung, Hong Kong. TATA Health International Holdings Limited is a subsidiary of Shang Ying Financial Holding Co., Limited.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

TATA Health International Holdings reported revenue of HK$99.8M in FY2025 versus HK$161M in FY2021, a compound −11.3%/yr. Reported net income was HK$13.4M in FY2025.

Growth Quality 19/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
HK$99.8M
Latest YoY
−19.8%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−11.6%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−8.5%
Avg. growth/yr (15Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−8.3%
Revenue −11.3%/yr
FY21 HK$161M
FY22 HK$145M
FY23 HK$208M
FY24 HK$124M
FY25 HK$99.8M
Net income
FY21 −HK$70.5M
FY22 HK$9.6M
FY23 −HK$32.3M
FY24 −HK$68.3M
FY25 HK$13.4M

1255 screens 45% overvalued. Compare with NIKE, Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "TATA Health International Holdings Fair Value". https://www.fairvalue-calculator.com/stock/1255

Peer Group

Footwear & Accessories · 93 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 59 · Above median
Fair Value upside −45% · Below median
Return on assets -13% · Bottom 25%
Net margin (TTM) 13% · Top 25%
Operating margin (TTM) -3% · Bottom 25%
Revenue growth 1% · Above median
Dividend yield (TTM) 0.5% · Bottom 25%

Valuation Multiples vs Footwear & Accessories median · lower = cheaper

P/E (TTM) 72.0× · Pricier than 75% of peers
P/S (TTM) 8.76× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 11
FUTURE 3 · sector 0
PAST 0 · sector 23
HEALTH 100 · sector 97
DIVIDEND 11 · sector 52

VALUE 0: the price sits above our fair-value range.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Footwear & Accessories stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
NIKE, Inc NKE $40.51 $35.63 -12%
adidas AG 1ADS €158.15 €65.71 -58%
Deckers Outdoor Corporation DECK $93.84 $125.16 +33%
On Holding ONON $30.91 $17.53 -43%
Zhejiang China Commodities City Group 600415 ¥11.81 ¥13.03 +10%
Birkenstock Holding BIRK $36.74 $44.59 +21%
Crocs, Inc CROX $130.61 $203.65 +56%
Huali Industrial Group 300979 ¥36.73 ¥51.36 +40%
PUMA SE PUM €26.69 €10.57 -60%
Yue Yuen Industrial (Holdings) Limited 0551 HK$13.64 HK$4.04 -70%

Compare TATA Health International Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Consumer Cyclical stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is TATA Health International Holdings (1255) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$1.21 versus a price of HK$2.20, about −45% (overvalued).
What is the fair value of 1255?
Our model-based fair value for TATA Health International Holdings is HK$1.21 (as of Aug 13, 2026), built from audited fundamentals. The current price is HK$2.20.
What is the quality score of 1255?
TATA Health International Holdings has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of TATA Health International Holdings (1255)?
TATA Health International Holdings reported trailing-twelve-month revenue of about HK$99.8M (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 1255?
The net profit margin of TATA Health International Holdings is about 13.4%, meaning it keeps roughly 13.4% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track TATA Health International Holdings and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.